We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Gossamer Bio (NASDAQ: GOSS) Finalizes Up to $250 Million Financing Tied to Seralutinib

Gossamer Bio, Inc. (NASDAQ: GOSS) finalized a private placement financing agreement for as much as $250 million linked to seralutinib development, featuring a $25 million upfront payment and $125 million contingent on FDA acceptance of the PAH NDA.

Nitish Kishor | 24 August 2026

Jupiter Neurosciences (NASDAQ: JUNS) Rises 21% on PharmAla MDMA Licensing Deal

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) shares closed up 21% at $6.28 after the company priced a $2.0 million registered direct offering of 307,692 shares, adding modest near-term capital.

Nitish Kishor | 24 August 2026

Jupiter Neurosciences (NASDAQ: JUNS) Secures Exclusive U.S. Rights to PharmAla's ALA-002

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) secured exclusive U.S. rights to PharmAla's patented non-racemic MDMA formulation ALA-002, giving Jupiter a psychedelic neuropsychiatric asset.

Nitish Kishor | 24 August 2026

Arcturus Therapeutics (NASDAQ: ARCT) Rises 22% on Cash Runway and Upcoming Catalysts

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares closed up 22% at $13.45 after the company reported a widened Q2 net loss of $23.8 million as collaboration revenue declined following reduced recognition from CSL Seqirus.

Nitish Kishor | 24 August 2026

Werewolf Therapeutics (NASDAQ: HOWL) to Merge With Ambros Therapeutics in All-Stock Deal

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) will merge with Ambros Therapeutics in an all-stock transaction to form Nasdaq-listed Ambros Therapeutics, shifting focus to neridronate for CRPS-1.

Nitish Kishor | 24 August 2026

Why Is Vanda Pharmaceuticals (NASDAQ:VNDA) Rising Pre-Market Today?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares ticked higher in pre-market trading after the company announced that its investigational drug imsidolimab received Orphan Designation from the European Commission for the treatment of Generalized Pustular Psoriasis, a severe and potentially life-threatening inflammatory skin disease. The designation marks …

Nitish Kishor | 24 August 2026

Why Is Virtuix Holdings (NASDAQ:VTIX) in the Spotlight Today?

Virtuix Holdings Inc. (NASDAQ:VTIX) was featured in a Bloomberg Television broadcast on August 22, spotlighting the company's immersive virtual reality technology alongside two other public companies addressing different market opportunities. The sponsored programming segment aired across Bloomberg Television in the United States, Latin America, …

Nitish Kishor | 24 August 2026

Why Is SI-BONE (NASDAQ:SIBN) Rising 4% Pre-Market Today?

SI-BONE, Inc. (NASDAQ:SIBN) shares climbed further in pre-market trading, extending recent momentum as investors weigh a series of heavy insider stock sales against strong underlying fundamentals following the company's second-quarterEarningsbeat. The stock's advance follows a string of bullish analyst actions, including initiating coverage with …

Nitish Kishor | 24 August 2026

Why Is SafeSpace Global (OTCID:SSGC) in the Spotlight Today?

SafeSpace Global Corporation (OTCID:SSGC) was featured in a Bloomberg Television broadcast on August 22, highlighting the company's artificial intelligence-powered physical security platform designed to help schools, senior-living facilities, and other organizations identify potential threats earlier. The sponsored programming segment aired alongside features on two …

Nitish Kishor | 24 August 2026

REGENXBIO (NASDAQ:RGNX) Falls 21% Pre-Market on FDA Clinical Hold

REGENXBIO Inc. (NASDAQ:RGNX) shares dropped sharply in pre-market trading after the U.S. Food and Drug Administration placed a clinical hold on RGX-121, the company's investigational gene therapy for Mucopolysaccharidosis type II, also known as Hunter Syndrome. The hold followed the discovery of asymptomatic spine …

Nitish Kishor | 24 August 2026
Support

Hi! How can we help you today?

Loading…